Vaxcyte (PCVX) Share-based Compensation (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Share-based Compensation data on file, last reported at $38.0 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $38.0 million, up 24.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $146.2 million (up 49.47% YoY), and the FY2025 annual result was $138.8 million, up 63.69% from the prior year.
• Share-based Compensation advanced to $38.0 million in Q1 2026 per PCVX's latest filing, from $36.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $38.0 million in Q1 2026 and troughed at $2.7 million in Q3 2022.
• A 5-year average of $18.6 million and a median of $17.6 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation jumped 500.2% in 2022, then advanced 0.29% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $7.0 million in 2022, then jumped by 90.44% to $13.3 million in 2023, then surged by 82.57% to $24.4 million in 2024, then jumped by 47.71% to $36.0 million in 2025, then increased by 5.46% to $38.0 million in 2026.
• Business Quant data shows PCVX's Share-based Compensation at $38.0 million in Q1 2026, $36.0 million in Q4 2025, and $35.3 million in Q3 2025.